Drug Trial Radar · NCT01131546
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,080
Planned (sponsor's estimate)
Start
Dec 2009
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
Conditions
- Essential Hypertension
Interventions
Levamlodipine besylateDrug
Once daily, 7AM - 10AM
Amlodipine maleateDrug
Once daily, 7AM - 10AM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients who reach overall blood pressure control (defined as BP <140/90 mmHg for non-diabetic patients and < 130/80 mmHg for diabetic patients)Time frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.